Freeline Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Freeline Therapeutics (NASDAQ:FRLN) is set to release its latest quarterly earnings report on August 15, 2023. Analysts estimate an earnings per share (EPS) of $-3.14. The company's past performance shows a pattern of beating EPS estimates, which has sometimes resulted in a share price increase. However, the stock has been down 71.07% over the last 52-week period.
August 14, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Freeline Therapeutics is expected to report an EPS of $-3.14 in its upcoming earnings. The company has a history of beating EPS estimates, which could potentially lead to a short-term increase in share price. However, the stock has been down 71.07% over the last year.
Freeline Therapeutics has a history of beating EPS estimates, which could potentially lead to a short-term increase in share price. However, the long-term trend of the stock is negative, with a 71.07% decrease over the last year. This could indicate that despite the potential positive earnings, the overall market sentiment towards the company is negative.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100